DNDi-developed African sleeping sickness treatment, first oral treatment approved by US FDA


Fexinidazole, the first oral treatment for sleeping sickness in Africa, developed by the Drugs for Neglected Diseases initiative (DNDi) in collaboration with the Democratic Republic of the Congo, the Central African Republic and Sanofi, has been approved by the US FDA.

Japanese version press release here English version press release here.

About African sleeping sickness
African sleeping sickness (also known as human-African trypanosomiasis) is usually fatal if left untreated. The bite of the tsetse fly causes infection in humans, and after a period of no specific symptoms, it progresses to neuropsychiatric symptoms such as aggressive behavior and sleep disorders due to the weakness that gave rise to the name of this disrespectful disease. .. Approximately 65 million people living in sub-Saharan Africa are at moderate to very high risk of infection.

About DND i
Drugs for Neglected Diseases initiative (DND i ) includes African sleeping sickness, Leishmania, Chagas disease, filaria infection, mycetoma, pediatric HIV, hepatitis C, and new coronavirus (COVID-19) infection. A non-profit research and development organization that works in partnership to research and develop safe, effective, and available treatments based on the needs of patients. Since its establishment in 2003, it has developed nine new therapies, including the combination of nifurtimox and eflornithine NECT for patients with late African sleeping sickness, and fexinidazole, the first oral treatment for African sleeping sickness. I delivered it to the patient. For more information, please visit www.dndi.org.

Source: https://www.dndijapan.org/2021/press-releases/pr-20210719/